Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.

Piha-Paul SA, Taylor MH, Spitz D, Schwartzberg L, Beck JT, Bauer TM, Meric-Bernstam F, Purkayastha D, Karpiak L, Szpakowski S, Braiteh F.

Oncotarget. 2019 Nov 5;10(60):6526-6535. doi: 10.18632/oncotarget.27251. eCollection 2019 Nov 5.

2.

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim SW, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim DW, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB.

J Thorac Oncol. 2018 Apr;13(4):576-584. doi: 10.1016/j.jtho.2017.11.131. Epub 2017 Dec 13.

3.

Using Bayesian modelling to investigate factors governing antibiotic-induced Candida albicans colonization of the GI tract.

Shankar J, Solis NV, Mounaud S, Szpakowski S, Liu H, Losada L, Nierman WC, Filler SG.

Sci Rep. 2015 Feb 3;5:8131. doi: 10.1038/srep08131.

4.

A systematic evaluation of high-dimensional, ensemble-based regression for exploring large model spaces in microbiome analyses.

Shankar J, Szpakowski S, Solis NV, Mounaud S, Liu H, Losada L, Nierman WC, Filler SG.

BMC Bioinformatics. 2015 Feb 1;16:31. doi: 10.1186/s12859-015-0467-6.

5.

Microbiome in human health and disease.

Madupu R, Szpakowski S, Nelson KE.

Sci Prog. 2013;96(Pt 2):153-70.

PMID:
23901633
6.

Next generation sequencing to define prokaryotic and fungal diversity in the bovine rumen.

Fouts DE, Szpakowski S, Purushe J, Torralba M, Waterman RC, MacNeil MD, Alexander LJ, Nelson KE.

PLoS One. 2012;7(11):e48289. doi: 10.1371/journal.pone.0048289. Epub 2012 Nov 7.

7.

Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury.

Fouts DE, Pieper R, Szpakowski S, Pohl H, Knoblach S, Suh MJ, Huang ST, Ljungberg I, Sprague BM, Lucas SK, Torralba M, Nelson KE, Groah SL.

J Transl Med. 2012 Aug 28;10:174. doi: 10.1186/1479-5876-10-174.

8.

Sequence-specific biosensors report drug-induced changes in epigenetic silencing in living cells.

Huang X, Narayanaswamy R, Fenn K, Szpakowski S, Sasaki C, Costa J, Blancafort P, Lizardi PM.

DNA Cell Biol. 2012 Oct;31 Suppl 1:S2-10. doi: 10.1089/dna.2011.1537. Epub 2012 Feb 7.

9.

MicroRNA signatures differentiate melanoma subtypes.

Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ, Weidhaas JB.

Cell Cycle. 2011 Jun 1;10(11):1845-52. Epub 2011 Jun 1.

10.

Phosphoproteomic screen identifies potential therapeutic targets in melanoma.

Tworkoski K, Singhal G, Szpakowski S, Zito CI, Bacchiocchi A, Muthusamy V, Bosenberg M, Krauthammer M, Halaban R, Stern DF.

Mol Cancer Res. 2011 Jun;9(6):801-12. doi: 10.1158/1541-7786.MCR-10-0512. Epub 2011 Apr 26.

11.

MU2A--reconciling the genome and transcriptome to determine the effects of base substitutions.

Garla V, Kong Y, Szpakowski S, Krauthammer M.

Bioinformatics. 2011 Feb 1;27(3):416-8. doi: 10.1093/bioinformatics/btq658. Epub 2010 Dec 12.

12.

Loss of epigenetic silencing in tumors preferentially affects primate-specific retroelements.

Szpakowski S, Sun X, Lage JM, Dyer A, Rubinstein J, Kowalski D, Sasaki C, Costa J, Lizardi PM.

Gene. 2009 Dec 15;448(2):151-67. doi: 10.1016/j.gene.2009.08.006. Epub 2009 Aug 21.

13.

Using semantic web technologies to annotate and align microarray designs.

Szpakowski S, McCusker J, Krauthammer M.

Cancer Inform. 2009 May 13;8:65-73. eCollection 2009.

Supplemental Content

Loading ...
Support Center